mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma.
about
Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of playThe Role of Autophagy in Hepatocellular CarcinomaTargeting the mTOR pathway in hepatocellular carcinoma: current state and future trendsWogonin induces Beclin-1/PI3K and reactive oxygen species-mediated autophagy in human pancreatic cancer cellsPotentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell LinesPhase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for responseA Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid MalignanciesIdentification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing.Tailoring mTOR-based therapy: molecular evidence and clinical challenges.RAD001 enhances the potency of BEZ235 to inhibit mTOR signaling and tumor growthThe mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas.BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancerA tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatmentsMolecular analysis of a male breast cancer patient with prolonged stable disease under mTOR/PI3K inhibitors BEZ235/everolimus.Anti-tumor efficacy of BEZ235 is complemented by its anti-angiogenic effects via downregulation of PI3K-mTOR-HIF1alpha signaling in HER2-defined breast cancers.Translation control during prolonged mTORC1 inhibition mediated by 4E-BP3.Vertical blockade of the IGFR- PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: the role of survivinPotentiation of the anticancer effects of everolimus using a dual mTORC1/2 inhibitor in hepatocellular carcinoma cells.The mTOR pathway in hepatic malignancies.Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition.Rationale of personalized immunosuppressive medication for hepatocellular carcinoma patients after liver transplantation.Therapeutic potential and adverse events of everolimus for treatment of hepatocellular carcinoma - systematic review and meta-analysis.Modulation of autophagy for the treatment of liver diseases.UNC51-like kinase 1, autophagic regulator and cancer therapeutic target.Targeting the tumor stroma in hepatocellular carcinoma.ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer.Zebrafish as a Model Organism for the Development of Drugs for Skin Cancer.K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines.The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models.Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action.Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma.AKT signalling is required for ribosomal RNA synthesis and progression of Eμ-Myc B-cell lymphoma in vivo.New insights into 4E-BP1-regulated translation in cancer progression and metastasis.Atg9b Deficiency Suppresses Autophagy and Potentiates Endoplasmic Reticulum Stress-Associated Hepatocyte Apoptosis in Hepatocarcinogenesis.mTOR in viral hepatitis and hepatocellular carcinoma: function and treatment.Reprofiling using a zebrafish melanoma model reveals drugs cooperating with targeted therapeutics.Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors.RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition.Autophagy Modulation in Cancer: Current Knowledge on Action and Therapy.Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity
P2860
Q26764911-6839EA57-DFAC-4D4F-A18D-D75643F81135Q26777419-B9BE3800-DC90-4D38-A06A-0B9387E0167BQ26830194-2C06C152-DA9E-410B-9739-C8CE8B9D31BEQ28468351-EEDDD4BC-72A8-4151-8F4A-14BD8ABC4E18Q28546221-ACC40310-A516-4353-ABC9-F8DCE72E641BQ33422744-CD0E8E78-0C61-4316-A831-DD4D64C43573Q33735754-189D0990-AD34-4B03-9A34-645D273F3DE0Q33917547-3AC35A40-C1F8-4039-82EC-D32E2BCE01B3Q34294170-C019EFDF-C1C7-4A41-AE69-B44DDB259C5FQ34479023-A94C847F-1CD5-4F0C-873C-291FCDA0A0A0Q34986247-005EB964-B6B1-415E-AB5F-D588BA668A4AQ36350128-FAF53E4D-2AAB-4FDF-BE6A-CD20314A0D81Q36740744-B614AE9E-56B2-4620-97AF-0D343BB4A09CQ36849266-A6DFF90A-7B74-4E29-AF71-B99E562CCAC7Q36879470-5A0A4EB6-89B5-4999-B26A-28214992AACAQ37024596-965BA1A0-F063-4BE8-BDD2-4E8D4D8F3709Q37438760-325F8F24-A778-4152-9F09-65BCCBD6338DQ37709404-22A4F9EC-69C3-4530-B146-B774673F8FF2Q38081396-642B5D6A-03E9-4C30-8839-1B7129EC4435Q38155511-72543622-277B-4441-A302-7F32F1BBB3A8Q38174585-5EC5C59E-CAED-4A6F-9263-EBECBB2880BAQ38176862-A8AE2912-624A-4B27-A065-ACCC050BB5D2Q38205866-2DFD7F6A-1DAC-4BC1-9C36-63EBA3AD3774Q38261262-63EC274F-3990-4F41-8C07-11772AC0C839Q38366586-F675588A-6C56-4F49-8D17-D0AE47B2FB00Q38532510-1C929018-B821-4DF6-A500-F290E3972523Q38656012-3C240DCC-19E7-4246-933B-9FE701EB1A4FQ38678966-8D49B3B9-21B9-4B5D-AF39-A6141685F3FCQ38995499-16872256-8740-40D6-ACFF-B13D2F90E35FQ39008859-6501761C-4383-4903-A0B3-944122E78D93Q39181242-8D154B0B-4EFC-4C87-9F9E-02DBC344400BQ39208340-D4DEE0A9-D4B9-4DD1-BEC0-CEB282940A9DQ40948168-DCB9956F-1426-489A-A39E-4EB85BAD1762Q40980450-55B9E3CA-4864-4620-8BD7-94DB1ED77601Q41233635-8515ABCF-7436-4777-8CC5-6A49CDEE9506Q42199220-55885E97-6C08-4D0D-83B4-462CBEEA02A6Q46392522-1484E513-D8B8-40E8-97C2-CF486C109484Q48123819-CF70C6EB-4BF4-47E6-841A-972C9F2467A9Q52592885-93385696-2A3A-4A43-9C87-91B9F5B700C8Q56892381-333855E5-2476-43DD-A4FB-DC5161E0768E
P2860
mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
mTOR inhibitors synergize on r ...... y in hepatocellular carcinoma.
@en
type
label
mTOR inhibitors synergize on r ...... y in hepatocellular carcinoma.
@en
prefLabel
mTOR inhibitors synergize on r ...... y in hepatocellular carcinoma.
@en
P2093
P2860
P50
P1476
mTOR inhibitors synergize on r ...... gy in hepatocellular carcinoma
@en
P2093
Akio Iwanami
Elizabeth A Conner
George Thomas
Hala Elnakat Thomas
Kazuhiro Tanaka
Liu Manway
Paul S Mischel
S Michel Maira
Sara C Kozma
Snorri S Thorgeirsson
P2860
P304
P356
10.1126/SCITRANSLMED.3003923
P407
P577
2012-04-25T00:00:00Z